How to treat Helicobacter pylori. First-line, second-line, and future therapies (Q34145476)

31 July 2017

1 reference

title

How to treat Helicobacter pylori. First-line, second-line, and future therapies (English)

1 reference

31 July 2017

0 references

2

Marshall BJ

1 reference

31 July 2017

Mégraud F

1

1 reference

31 July 2017

publication date

1 December 2000

1 reference

Gastroenterology Clinics of North America

31 July 2017

published in

1 reference

31 July 2017

volume

29

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

759-73, vii

1 reference

Helicobacter pylori therapy: effect on peptic ulcer disease

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Amoxycillin tolerance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Ranitidine bismuth citrate therapy regimens for treatment of Helicobacter pylori infection: a review.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Factors influencing the eradication of Helicobacter pylori with triple therapy

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Clarithromycin for the eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Evaluation of treatment regimens to cure Helicobacter pylori infection--a meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Clinical relevance of resistant strains of Helicobacter pylori: a review of current data

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Anti-helicobacter regimens

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Prospective evaluation of ranitidine bismuth citrate-based triple therapy for the treatment of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Novel therapies for Helicobacter pylori infection.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Review article: Helicobacter pylori eradication--understandable caution but no excuse for inertia

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. Gastrointestinal Physiology Working Group of the Universidad Peruana Cayetano Heredia and The Johns Hopkins University

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Gastric anti-secretory, mucosal protective, anti-pepsin and anti-Helicobacter properties of ranitidine bismuth citrate

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

The report of the Digestive Health InitiativeSM International Update Conference on Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Clinical relevance of the cagA, vacA, and iceA status of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

The only good Helicobacter pylori is a dead Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(05)70145-X

7 January 2021

Anti-helicobacter regimens

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/S0889-8553(05)70145-X

Latin-American Consensus Conference on Helicobacter pylori infection. Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE).

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/S0889-8553(05)70145-X

Identifiers

DOI

10.1016/S0889-8553(05)70145-X

1 reference

31 July 2017

1 reference